BVF Partners OS Ltd.
CIK 1660684 · last filed 2025-08-07
BVF Partners OS Ltd. is a corporate insider who has filed 17 SEC Form 4 insider transactions across 13 companies since 2017. The most recent filing, for EPIX, was dated Aug 7, 2025. Across all open-market trades the lifetime net is −$771.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $364.7M across reported positions. The firm reports its address in Grand Cayman, E9. 237 SEC filings were submitted jointly with BIOTECHNOLOGY VALUE FUND II LP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$364.74M
13
17
-$771.20M
Filer Profile
GRAND CAYMAN, E9 KY1-1104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ESSA Pharma Inc. (EPIX) Delisted | 4,726,809 | $0.20 | $951.0K | -$2.9K | 1 | 2025-08-07 | |
| ELDN | 145,029 | $2.78 | $403.2K | $0 | 1 | 2023-05-09 | |
| CTI BIOPHARMA CORP (CTIC) Delisted | Director | 62,978 | $9.09 | $572.5K | -$520.20M | 1 | 2022-08-11 |
| Merus N.V. (MRUS) Delisted | 311,210 | $90.00 | $28.01M | -$432.55M | 2 | 2021-07-07 | |
| Eledon Pharmaceuticals, Inc. (NVUS) Delisted | 771,780 | — | — | $0 | 1 | 2020-12-28 | |
| OLMA | 3,392,663 | $10.22 | $34.67M | $215.71M | 1 | 2020-11-20 | |
| XOMA Royalty Corp (XOMA) Delisted | 1,941,035 | $40.17 | $77.97M | $5.47M | 1 | 2020-08-25 | |
| KYMR | 1,359,109 | $114.96 | $156.24M | $0 | 1 | 2020-08-25 | |
| CYTK | 2,350,829 | $73.77 | $173.42M | -$118.47M | 1 | 2020-02-18 | |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 3,648,474 | $38.00 | $138.64M | $30.45M | 2 | 2019-12-11 | |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 5,815,887 | $0.04 | $260.0K | $8.55M | 1 | 2018-11-15 | |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | 291,788 | $8.37 | $2.44M | $36.80M | 1 | 2017-10-23 | |
| ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | 163,342 | — | — | $3.04M | 2 | 2017-05-19 |
Recent Filings
17 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-08-07 | ESSA Pharma Inc. (EPIX) Delisted | Mixed | +29,198,440 | -$10 | EDGAR |
| 2023-05-09 | ELDN | Buy (P) | +19,789,320 | $0 | EDGAR |
| 2022-08-11 | CTI BIOPHARMA CORP (CTIC) Delisted | Mixed | −1,166,690 | -$520.20M | EDGAR |
| 2021-07-07 | Merus N.V. (MRUS) Delisted | Sell (S) | −21,860,220 | -$453.60M | EDGAR |
| 2020-12-28 | Eledon Pharmaceuticals, Inc. (NVUS) Delisted | Conv (C) | +12,896,280 | $0 | EDGAR |
| 2020-11-20 | OLMA | Mixed | +63,520,100 | $215.71M | EDGAR |
| 2020-09-14 | Merus N.V. (MRUS) Delisted | Buy (P) | +1,896,510 | $21.05M | EDGAR |
| 2020-08-25 | XOMA Royalty Corp (XOMA) Delisted | Buy (P) | +281,750 | $5.47M | EDGAR |
| 2020-08-25 | KYMR | Mixed | +25,574,970 | $195.74M | EDGAR |
| 2020-02-18 | CYTK | Sell (S) | −7,504,210 | -$118.47M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.